Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1993-05-24
1997-09-09
Sayala, Chhaya D.
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
424 851, A61K 4505
Patent
active
056653450
ABSTRACT:
The present invention provides a method of inhibiting the replication of human immunodeficiency virus in cells which are infected with HIV comprising administering to the cells a replication inhibiting amount of interleukin-10. Also provided is a parenteral method of the administration of interleukin-10 administration. Further provided is a method of inhibiting retroviral replication in a human subject infected by a retrovirus, comprising administering to the subject an inhibiting amount of interleukin-10, including the retrovirus is. Finally, a method of treating Kaposi's sarcoma in a human subject comprising administering to the subject an effective amount of interleukin-10 to the subject is provided.
REFERENCES:
Akridge et al., J. Immunol., vol. 153, pp. 5782-5789, 1994.
Kootstra et al., J. Virology, vol. 68(11), pp. 6967-6975, 1994.
Emilie et al., Int. J. Immunopharmac., vol. 16 (5/6) pp. 391-396, 1994.
Fiorentino, D. F., M. W. Bond, and T. R. Mosmann. 1989. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp Med. 170:2081.
Howard, M., A. O'Garra, H. Ishida, R. De Waal Malefyt, and J. De Vries. 1992. Biological properties of interleukin-10. J Clin Immunol. 12:239.
Go, N. F., B. E. Castle, R. Barrett, R. Kastelein, W. Dang, T. R. Mosmann, K. W. Moore, and M. Howard. 1990. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med. 172:1625.
Bogdan, C., Y. Vodovotz, and C. Nathan. 1991. Macrophage deactivation by interleukin 10. J Exp Med. 174:1549.
de Waal Malefyt, R., J. Abrams, B. Bennett, C. G. Figdor, and J. E. de Vries. 1991. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 174:1209.
Vieira, P., R. de Waal Malefyt, M. N. Dang, K. E. Johnson, R. Kastelein, D. F. Fiorentino, J. E. deVries, M. G. Roncarolo, T. R. Mosmann, and K. W. Moore. 1991. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci U S A. 88:1172.
Thorley-Lawson, D. A. 1980. The suppression of Epstein-Barr virus infection in vitro occurs after infection but before transformation of the cell. J Immunol. 124:745.
Masucci, M. G., M. T. Bejarano, G. Masucci, and E. Klein. 1983. Large granular lymphocytes inhibit the in vitro growth of autologous Epstein-Barr virus-infected B cells. Cell Immunol. 76:311.
Gazzinelli, R. T., M. Makino, S. K. Chattopadhyay, C. M. Snapper, A. Sher, A. W. Hugin, and H. C. Morse III. 1992. CD4+ subset regulation in viral infection. Preferential activation of Th2 cells during progression of retrovirus-induced immunodeficiency in mice. J Immunol. 148:182.
Benjamin, D., T. J. Knobloch, and M. A. Dayton. 1992. Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood. 80:1289.
Mosier, Donald E., Richard J. Gulizia, Paul D. MacIsaac, Bruce E. Robett and Jay A. Levy. 1993. Rapid Loss of CD4.sup.+ T Cells in Human-PBL-SCID Mice by Noncytopathic HIV Isolates. Science, vol. 260, pp. 689-692.
Poli, G., A.L. Kinter, D. Weissman, P. Biswas and A.S. Fauci. 1993. Interactions Between Pro-Inflammatory and Immunoregulatory Cytokines Modulate the Expression of Human Immunodeficiency Virus in Monocytic Cells. Clinical Research, vol. 41, No. 2.
Chan et al., J. Exp Med, vol. 173, pp. 869-879, 1991.
Brok et al., J. Immunol., vol. 151, No. 11, pp. 6451-6459, 1993.
Roitt et al., "Immunology", Third Edition, Publishers: Mosby, Baltimore, pp. 8.12 to 8.16, 1993.
Saville et al., Blood, vol. 83(12), pp. 3591-3599, Jun. 1994.
Montaner et al., The Lancet, vol. 344, pp. 625-626, 1994.
Butera, J. Cell. Biochem., vol. 53, pp. 336-342, 1993.
Martin et al., Cancer Res., vol. 46, pp. 2189-2192, 1986.
Fox, BioTech., vol. 12, p. 128, 1994.
Fahey et al., Clin. Exp. Immunol., vol. 88, pp. 1-5, 1992.
Lane et al, The New England J Med, vol. 311(17), pp. 1099-1103, 1984.
Lane et al., Annals of Int. Med., vol. 103, pp. 714-718, 1985.
Hirsch, The Amer. J. Med., vol. 85 (Suppl. 2A), pp. 182-185, 1988.
Konrad, "Biological Barriers to Protein Delivery", ed. Audus et al., Plenum Press, pp. 409-437, 1993.
Meijer et al., Antiviral Res., vol. 18, pp. 215-258, 1992.
Wedner, Basic & Clin. Immunol., Ed Stites et al., Appleton & Lange, Chap 34, 1991.
Jansen et al., Pharm. Res., vol. 10(11), pp. 1611-1614, 1993.
Hsu et al., Int. Immunol., vol. 4 (5) pp. 563-569, 1991.
Folks et al., PNAS, vol. 86, pp. 2365-2368, 1989.
Osborn et al., PNAS, vol. 86, pp. 2336-2340, 1989.
de Waal Malefyt, J Exp Med., vol. 174, pp. 1209-1220, 1991.
Perno et al Blood, vol. 80, No. 4 (Aug. 15) 1992 pp. 995-1003.
Perno et al The Journal of Experimental Medicine, vol. 169, (Mar. 1989) pp. 993-951.
Clerici, Mario et al., "Changes in Inteleukin-2 and Interleukin-4 Production in Asymptomatic, Human Immunodeficiency Virus-seropositive Individuals", The Journal of Clinical Investigation, Inc., vol. 91, pp. 759-765, Mar. 1993.
Saville M. Wayne
Taga Kazuyuki
Tosato Giovanna
Yarchoan Robert
Sayala Chhaya D.
The United States of America as represented by the Department of
LandOfFree
Methods of inhibiting viral replication using IL-10 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting viral replication using IL-10, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting viral replication using IL-10 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-67511